The Salk approach, tested in a mouse model, points to cheaper and more effective treatments for humans
For most people with hemophilia B, whose bodies can’t properly form blood clots, constant injections to replenish their clotting factors are a way of life. But now, Salk researchers have demonstrated in mice that hemophilia B can be treated for life with one single injection containing disease-free liver cells that can produce their missing clotting factor. The finding, published in the journal Cell Reports on May 1, 2018, could drastically change what it means to be diagnosed with hemophilia B, and could pave the way toward similar treatments for other, related genetic disorders.
Hemophilia B is caused by defects in the gene for a protein called clotting factor IX (FIX). Hemophiliacs may make reduced amounts of the protein, or lack a functional version altogether, leading to life-threatening delays in blood clotting. Currently, patients are treated with injections—as often as a few times a week—containing FIX made in animal cells and then purified. But the approach is expensive, time-consuming and can become less effective over time.
Recently, Salk scientists developed a new approach, treating mice genetically engineered to have hemophilia B with strands of messenger RNA encoding the FIX gene. Like the standard treatment, however, this required repeat injections each time levels of the messenger RNA ran low. So the scientists wanted to try a more permanent approach: transplanting healthy liver cells, capable of producing FIX, into patients.
“The appeal of a cell-based approach is that you minimize the number of treatments that a patient needs,” says Suvasini Ramaswamy, a former Salk research associate in the Verma lab and first author of the new paper. “Rather than constant injections, you can do this in one shot.”
Since donor livers are often in short-supply, the researchers instead turned to stem-cell strategies to produce the healthy liver cells. They collected blood samples from two human patients with severe hemophilia B, who are unable to produce FIX. Then, in the lab, they reprogrammed the cells into induced pluripotent stem cells (iPSCs), which have the capability to turn into many other cell types, including liver. Using CRISPR/Cas9, a tool that can alter genes, they then repaired the mutations in each patient’s FIX gene. Finally, they coaxed those repaired cells to develop into liver precursor cells called hepatocyte-like cells (HLCs) and transplanted them into mice with hemophilia B.
Rather than perform surgery on hemophilic mice—a risky undertaking when their blood can’t always clot—the team transplanted the HLCs through the spleen to distribute the cells uniformly in the liver.
Not only did the new HLCs produce FIX, but they produced enough of the protein to allow the mice to form normal blood clots, and the cells continued to survive—and produce FIX—for at least a year after the transplantation.
In people with hemophilia, using their own cells to generate healthy HLCs, then transplanting them back into their bodies, could help avoid the immune complications that often accompany cell therapies. But more work is needed to translate the findings to the clinic.
“A lot of things have to happen before this can go into humans,” says Ramaswamy.
Already, she adds, the work demonstrates the value in combining stem-cell reprogramming and new gene-modifying approaches to treat genetic diseases.
The Latest on: Hemophilia B
via Google News
The Latest on: Hemophilia B
- On World Hemophilia Day, know about the ‘missing factors’ in your blood on April 17, 2019 at 3:55 am
Though there are various types of hemophilia, the most common ones are Hemophilia A and Hemophilia B. Hemophilia C, which is rarely found, is caused by the absence or low levels of clotting factor XI. ... […]
- Hemophilia Disease: Causes, Types and Symptoms on April 17, 2019 at 12:02 am
If bleeding is high then it can be deadly. Mainly there are two types of Hemophilia disease. Haemophilia A and Hemophilia B. - Haemophilia A lack factor 8. - Haemophilia B lacks factor 9 That is, the ... […]
- The global hemophilia market is expected to reach USD 16.9 billion by 2026 on April 16, 2019 at 4:24 pm
NEW YORK, April 16, 2019 /PRNewswire/ -- Hemophilia Market Analysis by Type (Hemophilia A, Hemophilia B, Hemophilia C), by Treatment (On-demand, Prophylaxis), by Therapy (Replacement Therapy, Gene ... […]
- Global Hemophilia Gene Therapy Market - Growth Trends, Boost Growth, Future Expectations, Key Developments and Opportunities to 2028 on April 15, 2019 at 11:42 pm
The main segments identified in hemophilia gene therapy market includes Types– Hemophilia A, Hemophilia B , Applications– Hemophilia A Gene Therapy, Hemophilia B Gene Therapy, and Key Manufacturers – ... […]
- New multidisciplinary clinic improving care for patients with hemophilia on April 15, 2019 at 11:34 pm
A less common type is hemophilia B, which is the result of an individual not having enough clotting factor IX (factor nine),” said Dr Abdelbari. Hemophilia is rare, with type A affecting around ... […]
- GC Pharma Marks 'World Hemophilia Day' on April 15, 2019 at 8:08 pm
Hemophilia A is more common than hemophilia B; hemophilia A affects about 150,000 people, whereas hemophilia B affects about 30,000 people worldwide. Treatment regimens typically include on-demand ... […]
- Gene-based factor VIIa prevents bleeding episodes in animals with hemophilia on April 15, 2019 at 12:06 pm
The disorder commonly occurs in two types, hemophilia A and hemophilia B, distinguished by which natural coagulation factor is affected. An absence or deficiency of blood factor VIII leads to ... […]
- Aptevo Therapeutics Reports IXINITY® and Pipeline Progress on April 15, 2019 at 8:03 am
IXINITY Update “Patient conversions onto IXINITY therapy have continued as awareness of IXINITY and Aptevo builds within the Hemophilia B community,” said Mike Adelman, Senior Vice President ... […]
- Grifols donations of blood clotting factor helping people with hemophilia globally on April 15, 2019 at 3:15 am
"World Hemophilia Day reminds us that there are tens of thousands ... GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE: GRF.P) and on the U.S. NASDAQ through ADRs ... […]
via Bing News